A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs IC 14 (Primary)
- Indications Motor neuron disease
- Focus Adverse reactions
- Sponsors Implicit Bioscience
- 12 Mar 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 Planned End Date changed from 30 May 2018 to 30 Aug 2018.